NASDAQ:ATHX - Athersys Stock Price, Price Target & More

$2.01 -0.05 (-2.43 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$2.01
Today's Range$2.00 - $2.10
52-Week Range$1.29 - $2.63
Volume523,005 shs
Average Volume620,370 shs
Market Capitalization$262.98 million
P/E Ratio-6.93
Dividend YieldN/A
Beta-0.85

About Athersys (NASDAQ:ATHX)

Athersys logoAthersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATHX
CUSIPN/A
Phone216-431-9900

Debt

Debt-to-Equity RatioN/A
Current Ratio3.09%
Quick Ratio3.09%

Price-To-Earnings

Trailing P/E Ratio-6.93
Forward P/E Ratio-5.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.71 million
Price / Sales68.17
Cash FlowN/A
Price / CashN/A
Book Value$0.20 per share
Price / Book10.05

Profitability

EPS (Most Recent Fiscal Year)($0.29)
Net Income$-32,240,000.00
Net Margins-869.50%
Return on Equity-123.22%
Return on Assets-94.58%

Miscellaneous

Employees66
Outstanding Shares125,830,000

How to Become a New Pot Stock Millionaire

Athersys (NASDAQ:ATHX) Frequently Asked Questions

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys (NASDAQ:ATHX) announced its quarterly earnings data on Tuesday, March, 13th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.04. The biopharmaceutical company earned $1.17 million during the quarter, compared to the consensus estimate of $0.42 million. Athersys had a negative net margin of 869.50% and a negative return on equity of 123.22%. The business's revenue was up 19.0% on a year-over-year basis. During the same period last year, the business earned ($0.10) EPS. View Athersys' Earnings History.

When is Athersys' next earnings date?

Athersys is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Athersys.

What price target have analysts set for ATHX?

1 Wall Street analysts have issued twelve-month price targets for Athersys' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate Athersys' stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Athersys.

What are Wall Street analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:
  • 1. Maxim Group analysts commented, "Athersys and the University of Texas Health Science Center at Houston (UTHealth) announced plans to initiate a P2 study of MultiStem for the treatment and prevention of complications after severe traumatic injury. $3.5M in grant funding will be used to support the study." (4/23/2018)
  • 2. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (4/18/2018)

Who are some of Athersys' key competitors?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:
  • Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer (Age 56)
  • William B.J. Lehmann Jr. J.D., President, Chief Operating Officer (Age 51)
  • John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director (Age 49)
  • Laura K. Campbell CPA, Senior Vice President - Finance (Age 53)
  • Lee E. Babiss Ph.D., Lead Independent Director (Age 61)
  • Jordan S. Davis, Independent Director (Age 55)
  • Ismail Kola, Independent Director (Age 60)
  • Lorin Jeffry Randall, Independent Director (Age 73)
  • Jack L. Wyszomierski, Independent Director (Age 61)

Has Athersys been receiving favorable news coverage?

Media coverage about ATHX stock has trended somewhat positive this week, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Athersys earned a coverage optimism score of 0.13 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.98 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $2.01.

How big of a company is Athersys?

Athersys has a market capitalization of $262.98 million and generates $3.71 million in revenue each year. The biopharmaceutical company earns $-32,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 66 workers across the globe.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]


MarketBeat Community Rating for Athersys (ATHX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  343
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Athersys (NASDAQ:ATHX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Athersys in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 198.51%. The high price target for ATHX is $6.00 and the low price target for ATHX is $6.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$6.00$9.50$9.50
Price Target Upside: 198.51% upside284.62% upside433.71% upside288.55% upside

Athersys (NASDAQ:ATHX) Consensus Price Target History

Price Target History for Athersys (NASDAQ:ATHX)

Athersys (NASDAQ:ATHX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/23/2018Maxim GroupInitiated CoverageBuy$6.00MediumView Rating Details
3/28/2017William BlairReiterated RatingOutperformHighView Rating Details
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Athersys (NASDAQ:ATHX) Earnings History and Estimates Chart

Earnings by Quarter for Athersys (NASDAQ:ATHX)

Athersys (NASDAQ:ATHX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.33)
2019 EPS Consensus Estimate: ($0.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.10)($0.10)($0.10)
Q2 20181($0.02)($0.02)($0.02)
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.11)($0.11)($0.11)
Q1 20191($0.12)($0.12)($0.12)
Q2 20191($0.13)($0.13)($0.13)
Q3 20191($0.12)($0.12)($0.12)
Q4 20191($0.13)($0.13)($0.13)

Athersys (NASDAQ ATHX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.09)N/AView Earnings Details
3/13/2018Q4 2017($0.07)($0.11)$0.42 million$1.17 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.06)($0.06)$0.67 million$0.40 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.06)($0.06)$0.96 million$0.67 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.0670)($0.06)$0.45 million$1.50 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.08)($0.10)$0.45 million$0.98 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.10)($0.07)$0.60 million$0.31 millionViewListenView Earnings Details
8/9/2016Q216($0.10)($0.08)$0.32 million$0.60 millionViewN/AView Earnings Details
5/5/2016Q1($0.08)$0.06$1.85 million$15.45 millionViewN/AView Earnings Details
3/10/2016Q4($0.09)$0.04$3.72 million$10.61 millionViewListenView Earnings Details
11/5/2015Q315($0.07)($0.08)$1.75 million$0.40 millionViewListenView Earnings Details
8/6/2015Q2($0.08)$0.02$2.66 million$0.22 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.16)$2.01 million$0.73 millionViewListenView Earnings Details
3/12/2015Q414($0.09)($0.08)$0.50 million$0.24 millionViewN/AView Earnings Details
11/10/2014Q314($0.09)($0.11)$0.54 million$0.29 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.06)$0.70 million$0.40 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.09)$0.66 million$0.71 millionViewN/AView Earnings Details
3/13/2014Q413($0.11)($0.15)$1.81 million$0.92 millionViewN/AView Earnings Details
11/14/2013Q3($0.12)($0.10)$0.49 million$0.6210 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.12)($0.11)$390.00 million$0.5710 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.11)($0.18)$1.58 million$0.3260 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.12)($0.09)ViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.12)$2.51 million$1.00 millionViewN/AView Earnings Details
8/13/2012Q2 2012($0.16)($0.13)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.14)($0.17)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.14)($0.18)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.17)($0.10)ViewN/AView Earnings Details
8/10/2011Q2 2011($0.13)($0.14)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.12)($0.18)ViewN/AView Earnings Details
3/14/2011Q4 2010($0.16)($0.11)ViewN/AView Earnings Details
11/8/2010Q3 2010($0.17)($0.19)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.14)($0.16)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.20)($0.14)ViewN/AView Earnings Details
3/11/2010Q4 2009($0.26)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.18)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.18)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.19)ViewN/AView Earnings Details
3/12/2009Q4 2008($0.26)($0.25)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.28)($0.24)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.26)($0.22)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.25)($0.25)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.25)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Athersys (NASDAQ:ATHX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Athersys (NASDAQ ATHX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 19.31%
Insider Trading History for Athersys (NASDAQ:ATHX)
Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Athersys (NASDAQ ATHX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/20/2018William Lehmann JrInsiderSell14,000$1.89$26,460.00481,973View SEC Filing  
3/16/2018John J HarringtonEVPSell15,000$1.84$27,600.00View SEC Filing  
12/19/2017William Lehmann JrCOOSell14,000$1.80$25,200.00503,712View SEC Filing  
12/18/2017John J HarringtonEVPSell7,500$1.77$13,275.00658,474View SEC Filing  
12/15/2017John J HarringtonEVPSell7,500$1.68$12,600.00658,474View SEC Filing  
9/19/2017William Lehmann JrInsiderSell15,000$2.38$35,700.00527,380View SEC Filing  
9/18/2017John J HarringtonEVPSell15,000$2.17$32,550.00679,416View SEC Filing  
6/16/2017John J HarringtonEVPSell36,000$1.45$52,200.00712,743View SEC Filing  
2/1/2017Ismail KolaDirectorBuy15,000$1.01$15,150.0015,000View SEC Filing  
2/1/2017Laura K CampbellInsiderBuy20,000$1.01$20,200.00501,815View SEC Filing  
12/19/2016William Lehmann JrInsiderSell3,000$1.60$4,800.00395,101View SEC Filing  
12/16/2016John J HarringtonEVPSell15,000$1.60$24,000.00599,392View SEC Filing  
9/19/2016William Lehmann JrInsiderSell3,000$1.96$5,880.00403,459View SEC Filing  
9/16/2016John J HarringtonEVPSell15,000$1.96$29,400.00619,639View SEC Filing  
6/21/2016William Lehmann JrCOOSell25,000$2.17$54,250.00279,017View SEC Filing  
3/21/2016William Lehmann JrCOOSell25,000$2.41$60,250.00319,720View SEC Filing  
12/21/2015William Lehmann, Jr.COOSell25,000$1.03$25,750.00335,346View SEC Filing  
9/21/2015Bokkelen Gil VanCEOSell9,500$1.36$12,920.00901,665View SEC Filing  
9/21/2015John J. HarringtonEVPSell8,150$1.36$11,084.00531,056View SEC Filing  
9/21/2015William Lehmann, Jr.COOSell25,000$1.36$34,000.00376,049View SEC Filing  
6/22/2015William Lehmann JrCOOSell25,000$1.21$30,250.00View SEC Filing  
6/19/2015John J HarringtonInsiderSell8,150$1.23$10,024.50View SEC Filing  
6/19/2015Robert J DeansEVPSell5,080$1.23$6,248.40View SEC Filing  
6/9/2015Kenneth H TraubDirectorBuy30,000$1.27$38,100.00View SEC Filing  
3/20/2015William Lehmann JrCOOSell25,000$3.14$78,500.00View SEC Filing  
3/19/2015Bokkelen Gil VanCEOSell9,500$3.10$29,450.00View SEC Filing  
3/19/2015Robert J DeansEVPSell5,080$3.10$15,748.00View SEC Filing  
12/19/2014Bokkelen Gil VanCEOSell9,500$1.29$12,255.00View SEC Filing  
12/19/2014Robert J DeansEVPSell5,080$1.28$6,502.40View SEC Filing  
12/19/2014William Lehmann JrCOOSell30,000$1.29$38,700.00View SEC Filing  
9/24/2014Kenneth H TraubDirectorBuy30,000$1.39$41,700.00View SEC Filing  
9/22/2014William Lehmann JrCOOSell30,000$1.40$42,000.00View SEC Filing  
9/19/2014Bokkelen Gil VanCEOSell9,500$1.41$13,395.00View SEC Filing  
9/19/2014John J HarringtonInsiderSell8,150$1.41$11,491.50View SEC Filing  
9/19/2014Robert J DeansEVPSell5,080$1.41$7,162.80View SEC Filing  
8/18/2014Lorin RandallDirectorSell15,000$1.54$23,100.00View SEC Filing  
6/20/2014William Lehmann JrCOOSell12,000$1.58$18,960.00View SEC Filing  
6/19/2014Bokkelen Gil VanCEOSell9,500$1.63$15,485.00View SEC Filing  
6/19/2014John J HarringtonInsiderSell8,150$1.63$13,284.50View SEC Filing  
6/19/2014Robert J DeansEVPSell5,080$1.63$8,280.40View SEC Filing  
6/19/2014William Lehmann JrCOOSell13,000$1.62$21,060.00View SEC Filing  
3/20/2014William Lehmann JrCOOSell25,000$3.62$90,500.00View SEC Filing  
3/18/2014Bokkelen Gil VanCEOSell9,500$3.54$33,630.00View SEC Filing  
3/18/2014John J HarringtonInsiderSell8,150$3.54$28,851.00View SEC Filing  
3/18/2014Robert J DeansEVPSell5,080$3.54$17,983.20View SEC Filing  
12/20/2013William Lehmann JrCOOSell25,000$2.13$53,250.00View SEC Filing  
12/11/2013Kenneth H TraubDirectorBuy20,000$1.94$38,800.00View SEC Filing  
9/20/2013John J HarringtonInsiderSell30,000$1.82$54,600.00View SEC Filing  
9/20/2013William Lehmann JrCOOSell12,000$1.83$21,960.00View SEC Filing  
11/28/2012Laura K CampbellVPBuy10,000$1.01$10,100.00View SEC Filing  
11/15/2012Robert J DeansEVPBuy3,500$0.99$3,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Athersys (NASDAQ ATHX) News Headlines

Source:
DateHeadline
Athersys (ATHX) Earns Buy Rating from Analysts at Maxim GroupAthersys (ATHX) Earns Buy Rating from Analysts at Maxim Group
www.americanbankingnews.com - April 23 at 10:54 AM
BRIEF-Uthealth In Houston And Athersys Announce Funding For Clinical Trial Using Multistem® To Treat Trauma ...BRIEF-Uthealth In Houston And Athersys Announce Funding For Clinical Trial Using Multistem® To Treat Trauma ...
www.reuters.com - April 23 at 8:15 AM
UTHealth in Houston and Athersys Announce Funding for Clinical Trial using MultiStem® to Treat Trauma PatientsUTHealth in Houston and Athersys Announce Funding for Clinical Trial using MultiStem® to Treat Trauma Patients
finance.yahoo.com - April 23 at 8:15 AM
Athersys (ATHX) Cut to Hold at Zacks Investment ResearchAthersys (ATHX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 18 at 6:22 PM
Athersys (ATHX) Upgraded to "Buy" at Zacks Investment ResearchAthersys (ATHX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 6:28 PM
Athersys/Healios Warrant Structure Bullish For Athersys SharesAthersys/Healios Warrant Structure Bullish For Athersys Shares
seekingalpha.com - April 16 at 5:25 PM
Athersys to Host First Quarter Financial Results CallAthersys to Host First Quarter Financial Results Call
finance.yahoo.com - April 12 at 5:39 PM
Edited Transcript of ATHX conference call or presentation 28-Jul-10 8:30pm GMTEdited Transcript of ATHX conference call or presentation 28-Jul-10 8:30pm GMT
finance.yahoo.com - April 12 at 5:39 PM
ValuEngine Downgrades Athersys (ATHX) to SellValuEngine Downgrades Athersys (ATHX) to Sell
www.americanbankingnews.com - April 8 at 1:29 PM
Wired News – Reata Pharma Reports Positive Top-line Data from its Phase-2 LARIAT TrialWired News – Reata Pharma Reports Positive Top-line Data from its Phase-2 LARIAT Trial
finance.yahoo.com - March 26 at 8:22 AM
Athersys (ATHX) Upgraded to Hold at ValuEngineAthersys (ATHX) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - March 23 at 11:22 PM
Analyzing Athersys (ATHX) and ARMO BioSciences (ARMO)Analyzing Athersys (ATHX) and ARMO BioSciences (ARMO)
www.americanbankingnews.com - March 23 at 3:26 AM
Insider Selling: Athersys, Inc. (ATHX) Insider Sells 14,000 Shares of StockInsider Selling: Athersys, Inc. (ATHX) Insider Sells 14,000 Shares of Stock
www.americanbankingnews.com - March 21 at 1:26 PM
Athersys to Present at Needham Healthcare Conference on March 28Athersys to Present at Needham Healthcare Conference on March 28
feeds.benzinga.com - March 20 at 2:31 PM
Athersys, Inc. (ATHX) EVP John J. Harrington Sells 15,000 SharesAthersys, Inc. (ATHX) EVP John J. Harrington Sells 15,000 Shares
www.americanbankingnews.com - March 19 at 8:30 PM
Athersys (ATHX) Buy Rating Reiterated at Maxim GroupAthersys' (ATHX) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - March 18 at 10:24 AM
Edited Transcript of ATHX earnings conference call or presentation 13-Mar-18 8:30pm GMTEdited Transcript of ATHX earnings conference call or presentation 13-Mar-18 8:30pm GMT
finance.yahoo.com - March 18 at 8:17 AM
Brokers Issue Forecasts for Athersys, Inc.s Q1 2018 Earnings (ATHX)Brokers Issue Forecasts for Athersys, Inc.'s Q1 2018 Earnings (ATHX)
www.americanbankingnews.com - March 16 at 8:50 AM
Brokers Set Expectations for Athersys, Inc.s Q1 2019 Earnings (ATHX)Brokers Set Expectations for Athersys, Inc.'s Q1 2019 Earnings (ATHX)
www.americanbankingnews.com - March 15 at 11:44 AM
Athersys (ATHX) Announces  Earnings Results, Misses Estimates By $0.04 EPSAthersys (ATHX) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - March 14 at 8:44 AM
A Bombshell Day For Athersys: Earnings, Partnership, And New Indications - Seeking AlphaA Bombshell Day For Athersys: Earnings, Partnership, And New Indications - Seeking Alpha
seekingalpha.com - March 14 at 8:32 AM
Athersys, Inc.: Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem CollaborationAthersys, Inc.: Athersys and Healios Announce Binding Letter of Intent to Expand MultiStem Collaboration
www.finanznachrichten.de - March 13 at 7:17 PM
Athersys Reports Financial Results for Fourth Quarter, Full Year 2017Athersys Reports Financial Results for Fourth Quarter, Full Year 2017
finance.yahoo.com - March 13 at 7:17 PM
Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® Collaboration - GlobeNewswire (press release)Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® Collaboration - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM
Athersys and Healios Announce Binding Letter of Intent to Expand ... - GlobeNewswire (press release)Athersys and Healios Announce Binding Letter of Intent to Expand ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 8:25 AM
Athersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® CollaborationAthersys and HEALIOS Announce Binding Letter of Intent to Expand MultiStem® Collaboration
finance.yahoo.com - March 13 at 8:25 AM
Athersys (ATHX) Downgraded by ValuEngineAthersys (ATHX) Downgraded by ValuEngine
www.americanbankingnews.com - March 4 at 11:42 PM
Athersys (ATHX) Scheduled to Post Quarterly Earnings on WednesdayAthersys (ATHX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:24 AM
Athersys: Is It Worth Your Time? - Seeking AlphaAthersys: Is It Worth Your Time? - Seeking Alpha
seekingalpha.com - February 21 at 8:21 AM
Selling Into A Void - Athersys Moves In Ignorance - Seeking AlphaSelling Into A Void - Athersys Moves In Ignorance - Seeking Alpha
seekingalpha.com - February 16 at 8:17 AM
Athersys (ATHX) Given a $6.00 Price Target at Maxim GroupAthersys (ATHX) Given a $6.00 Price Target at Maxim Group
www.americanbankingnews.com - February 13 at 5:24 PM
Athersys Enters Into New $100 Million Equity Facility with Aspire Capital - GlobeNewswire (press release)Athersys Enters Into New $100 Million Equity Facility with Aspire Capital - GlobeNewswire (press release)
globenewswire.com - February 4 at 9:25 AM
Athersys Enters Into New $100 Million Equity Facility with Aspire CapitalAthersys Enters Into New $100 Million Equity Facility with Aspire Capital
feeds.benzinga.com - February 2 at 7:45 AM
This Mornings Technical Outlook on Biotech Stocks -- Aptose Biosciences, Athersys, AVEO Pharma, and Aviragen TherapeuticsThis Morning's Technical Outlook on Biotech Stocks -- Aptose Biosciences, Athersys, AVEO Pharma, and Aviragen Therapeutics
www.bizjournals.com - February 1 at 9:39 AM
Athersys CEO to Speak at the 2018 Brain Health SummitAthersys CEO to Speak at the 2018 Brain Health Summit
feeds.benzinga.com - January 29 at 6:52 AM
Athersys (ATHX) & ZS Pharma (ZSPH) Critical AnalysisAthersys (ATHX) & ZS Pharma (ZSPH) Critical Analysis
www.americanbankingnews.com - January 22 at 7:24 PM
Athersys, Inc. (ATHX) EVP John J. Harrington Sells 7,500 SharesAthersys, Inc. (ATHX) EVP John J. Harrington Sells 7,500 Shares
www.americanbankingnews.com - December 19 at 6:52 PM
Athersys, Inc. (ATHX) COO William Lehmann, Jr. Sells 14,000 SharesAthersys, Inc. (ATHX) COO William Lehmann, Jr. Sells 14,000 Shares
www.americanbankingnews.com - December 19 at 6:26 PM
Athersys (ATHX) Downgraded by ValuEngine to "Sell"Athersys (ATHX) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 5 at 10:50 PM
Athersys, Inc. (ATHX) Rating Increased to Hold at ValuEngineAthersys, Inc. (ATHX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - November 23 at 12:46 AM
Maxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price TargetMaxim Group Analysts Give Athersys, Inc. (ATHX) a $12.00 Price Target
www.americanbankingnews.com - November 16 at 10:18 PM
HEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem® Treatment for Ischemic StrokeHEALIOS Announces Enrollment of First Patient in Japan in TREASURE Study of MultiStem® Treatment for Ischemic Stroke
finance.yahoo.com - November 16 at 11:35 AM
 Brokerages Set $12.00 Price Target for Athersys, Inc. (ATHX) Brokerages Set $12.00 Price Target for Athersys, Inc. (ATHX)
www.americanbankingnews.com - November 13 at 7:30 PM
Stocks Under Scanner in the Biotech Space -- Sangamo Therapeutics, Vertex Pharma, Athersys, and AVEO Pharma - PR Newswire (press release)Stocks Under Scanner in the Biotech Space -- Sangamo Therapeutics, Vertex Pharma, Athersys, and AVEO Pharma - PR Newswire (press release)
www.prnewswire.com - November 10 at 1:41 PM
Edited Transcript of ATHX earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of ATHX earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 5:19 PM
Athersys Reports Third Quarter 2017 Results - GlobeNewswire (press release)Athersys Reports Third Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 4:29 AM
Athersys, Inc. to Host Earnings CallAthersys, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 6:24 PM
Athersys Reports Third Quarter 2017 ResultsAthersys Reports Third Quarter 2017 Results
finance.yahoo.com - November 8 at 6:24 PM
Athersys, Inc. (ATHX) Scheduled to Post Quarterly Earnings on TuesdayAthersys, Inc. (ATHX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 9:58 AM
Bears On Parade - Regardless, Athersys Is Developing Key Relationships For A Successful FutureBears On Parade - Regardless, Athersys Is Developing Key Relationships For A Successful Future
seekingalpha.com - October 14 at 2:43 AM

SEC Filings

Athersys (NASDAQ:ATHX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Athersys (NASDAQ:ATHX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Athersys (NASDAQ ATHX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.